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Background: People with kidney failure typically receive kidney replacement therapy 
(KRT) in the form of dialysis or transplantation. However, studies have suggested that not 
all patients with kidney failure are best suited for KRT. Additionally, KRT is costly and not 
always accessible in resource-restricted settings. Conservative kidney management is an 
alternate kidney failure therapy, which focuses on symptom management, psychological 
health, spiritual care and family and social support. Despite the importance of conservative 
kidney management in kidney failure care, several barriers exist that impact its uptake and 
quality.  
 
Methods: The Global Kidney Health Atlas is an ongoing initiative of the International Society 
of Nephrology (ISN), which aims to monitor and evaluate the status of global kidney care 
worldwide. This study reports on findings from the 2018 Global Kidney Health Atlas 
survey, specifically addressing the availability, accessibility, uptake and quality of 
conservative kidney management.  
 
Results: Respondents from 160 countries completed the survey and 154 answered 
questions pertaining to conservative kidney management. Of these, 124 (81%) stated that 
conservative kidney management was available. Accessibility was low worldwide, 
particularly in low-income countries. Less than half of countries utilized multidisciplinary 
teams (46%), shared decision-making (32%), or provided psychological, cultural, or 
spiritual support (36%). One quarter provided relevant healthcare providers with training 
on conservative kidney management delivery. 
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Conclusions: Overall, conservative kidney management is available in most countries; 






The default medical decision for people with kidney failure (an estimated glomerular 
filtration rate ( eGFR) less than 15mL/min/1.73m2) is to offer them kidney replacement 
therapy (KRT), either dialysis or kidney transplantation. However, dialysis does not always 
improve outcomes, has several limitations, and may not be desirable for some patients, 
particularly older adults1. Similarly, kidney transplantation is not always feasible or 
optimal for patients.  
 
Even for those whom would benefit most from KRT, this treatment is not always an option. 
Organ shortage and limitations in resources required for surgery or post-operative care 
(for example, immunosuppressants) often limit access to kidney transplantation. Dialysis is 
also an expensive modality and may not be widely available or accessible either because a 
country or region is unable to cover the costs to offer the service, or because individuals 
are unable to pay the accompanying out of pocket expenses. Limitations in other economic 
and social resources required for dialysis such as transportation fees, may further impose 
barriers on the accessibility of treatment for patients, possibly more common among older 
adults.  
 
Therefore, selecting the most appropriate treatment for kidney failure requires careful 
consideration of the individual patient’s conditions, social circumstances, wishes, 
preferences, and life goals. Conservative kidney management focuses on supporting the 
needs of patients through symptom management, psychological therapy, or family and 
social support2 and is an alternative to patients unlikely to benefit from KRT (i.e., chosen or 
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medically advised) or unable to access KRT (i.e., choice-restricted). Recommendations on 
how to optimally deliver conservative kidney management, focused on the patient’s values 
and preferences, minimizing symptoms due to disease, and improving comfort and quality 
of life, are available to help guide practice3, 4.  
 
Despite the potential of conservative kidney management as a therapy for kidney failure, 
its utilization across the globe is unknown. Limited evidence on health outcomes makes 
decision-making for nephrologists a challenge5 and may result in the exclusion of 
conservative kidney management from kidney care policies. Additionally, as the awareness 
of conservative kidney management is relatively low, limited healthcare provider training, 
public expectations of what is considered more active care, and remuneration for care may 
impede its adoption6.  
 
Our objective for this study was to identify the current availability and accessibility of 
conservative kidney management worldwide. Additionally, we were interested in the 
quality of delivery in countries that do offer conservative kidney management. We 
leveraged data from the second Global Kidney Health Atlas (GKHA) survey7, which focused 
on kidney failure care including KRT and conservative kidney management.  
 
Methods 
As described elsewhere7-9, the GKHA is a project of the International Society of Nephrology 
(ISN) targeted at improving the global capacity of kidney care through an international 
survey of stakeholders. Details on the survey development and validation have previously 
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been published8, 9. To date, two iterations of the survey have been conducted (2016 and 
2018)10. Survey items pertaining to conservative kidney management were not included in 
the 2016 survey but were added to the second iteration. Here, we utilize the 2018 version 
to report on items specific to conservative kidney management (Supplementary Item S1).  
 
Key kidney care stakeholders (nephrology leaders, consumers, healthcare policy makers) 
were invited to participate based on their knowledge of kidney care and ability to 
accurately represent their country. In total, 2-3 representatives of 182 countries received 
an invitation to participate in the survey. We administered the survey online via REDCap 
Cloud (www.redcapcloud.com) from July to September 2018. We stored data in a 
centralized database and checked for inconsistencies within country responses. We asked 
ISN regional leaders to clarify discrepancies and subsequently updated the database. We 
imported the database into Stata 15 software (Stata Corporation, 2017). We analyzed data 
using descriptive statistics and reported findings as an overall aggregate score, stratified by 
ISN region11, and by World Bank income group. Country was the unit of analysis. The chi-
squared (χ²) test was used to examine differences in conservative kidney management 
accessibility and quality in this study. 
 
A definition of conservative kidney management was provided in the survey 
(Supplementary Item S1), following the Kidney Disease Improving Global Outcomes 
(KDIGO) recommendations. Conservative kidney management was defined as “planned, 
holistic, patient-centered care for patients with chronic kidney disease (CKD) stage 5, that 
includes interventions to delay progression of kidney disease and minimize complications 
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but focuses predominantly on symptom management and psychological, social, cultural 
and spiritual support but does not include dialysis” according to KDIGO2. It was further 
described that conservative kidney management could be administered as a chosen or 
medically advised treatment (i.e., an appropriate treatment modality for patients who 
choose not to initiate KRT) or as a choice-restricted treatment (i.e., in whom resource 
constraints prevent or limit access to KRT).  
 
Respondents were asked to report whether conservative kidney management was 
available in their country (yes/no/unknown) and for those with conservative kidney 
management, the availability of chosen or medically advised and choice-restricted care. 
Further, respondents were asked to rank its accessibility across settings (for example, 
home, hospital, hospice, and nursing home). Lastly, respondents were asked to rate the 
quality of conservative kidney management, as measured by the general availability of the 
following five domains: i) multidisciplinary team approaches, ii) tools for shared decision-
making (i.e., practice guidelines for providers or patient decision aids), iii) systematic 
active recognition and management of symptoms associated with kidney failure, iv) 
psychological, cultural, and spiritual support, and v) additional training to healthcare 
providers for conservative kidney management (Supplementary Item S1).   
 
The University of Alberta Research Ethics Committee approved this project (Protocol 






Survey response rate 
Of the 182 countries that received an invitation to participate in the 2018 survey, 
respondents from 160 (88%) participated. Of these, 311 respondents from 154 (96%) 
countries answered the survey item related to conservative kidney management 
availability (Supplementary Item S1; C.6.1). Of the 311 respondents, 82% were 
nephrologists, 7% were non-nephrologist physicians, 5% were administrators or 
policymakers, 2% were non-physician healthcare providers, and 4% reported another 
profession. Countries across all income groups were represented: 22 of the 23 (96%) low 
income countries responded to the survey question about conservative kidney 
management, as did 35/38 (92%) of lower-middle, 41/41 (100%) of upper-middle, and 
56/58 (97%) of high income countries.  
 
Conservative kidney management availability and accessibility 
Overall, respondents from 124/154 countries (81%) stated that conservative kidney 
management was available (Table 1). Income level was not associated with its availability . 
Of the 124 countries offering conservative kidney management, hemodialysis was available 
in all. Twenty-five countries (21%) do not have peritoneal dialysis available and 34 (27%) 
do not have kidney transplantation available. Eighteen countries (15%) have neither 
peritoneal dialysis nor transplantation available: 14 in Africa, one in Latin America, 2 in 





Respondents from 28 of the 154 countries reported that conservative kidney management 
was not available (Table 2). Of these 28 countries, all provided hemodialysis services, 23 
(82%) offer peritoneal dialysis, and 21 (75%) offer kidney transplantation. The majority of 
countries that lacked conservative kidney management, fund KRT either exclusively by the 
government with no fees (n=10) or through a mix of public and private sources (n=10) 
(Table 2). Four countries funded KRT through the government, with some fees at the point 
of delivery. Two countries funded KRT exclusively through private (i.e., out-of-pocket). One 
country funded KRT through multiple sources (i.e., programs provided by government, 
non-government organizations, and communities). One country selected ‘Other’ as the 
funding structure for KRT.  
 
Of the 124 countries with conservative kidney management available, 47 (38%) offer  
services that are easily accessible across settings (for example, at the patient’s home, 
hospital, hospice, and nursing home) (Table 1). Accessibility to conservative kidney 
management services was significantly different across the four income levels (χ2=33.2, 
p<0.001): high-income (32/47; 68%), upper-middle (9/33; 27%), lower-middle (6/26; 
23%), and low-income countries (0/18; 0%).  
 
Chosen or medically advised conservative kidney management 
Among countries with conservative kidney management available, respondents from 77 
(62%) reported that chosen or medically advised conservative kidney management was 
generally available. This was highest in North America (6/6) and Western Europe (18/18). 
Less than half of countries in South Asia (1/7), the Middle East (2/9), Latin America (3/8), 
 
 12 
and Oceania and South East Asia (6/14) reported that it was selected by choice or following 
medical advice. The availability of chosen or medically advised conservative kidney 
management was higher with increasing income level: 33% of low, 39% of lower-middle, 
64% of upper-middle, and 85% of high-income countries reported availability. Of the 77 
countries that generally offered chosen or medically advised conservative kidney 
management, 39 (51%) funded KRT publicly with no fees to patients at the point of care 
delivery; 15 (19%) funded KRT publicly with some fees to patients; 16 (21%) funded KRT 
through a mix of public and private sources; 3 (4%) funded through multiple sources (i.e., 
government, nongovernment organizations, communities); 3 (4%) funded solely through 
private; and one country (1%) reported an ‘Other’ type of funding model for KRT.  
 
Quality of conservative kidney management services 
Five indicators were used to assess the quality of conservative kidney management 
services (Table 3).  Of the countries that offered  services, respondents from 57 (46%) 
reported that multidisciplinary teams were generally available among centers. Forty (32%) 
incorporated shared decision-making; 80 (65%) had processes in place to systematically 
recognize and manage symptoms; 45 (36%) provided psychological, cultural, or spiritual 
support; and 31 (25%) provided relevant healthcare providers with additional training on 
how to deliver conservative kidney management (Table 3). Across every indicator, high-
income countries reported a greater presence of quality metrics and low-income countries 
reported they generally were not available, particularly for provider training (0%), shared 
decision-making (11%), and psychological, cultural, spiritual support (17%) 
(Supplementary Table S2). Among countries offering conservative kidney management, 
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respondents from 33 (27%) reported that no quality indicators were generally available 
and respondents from 26 (21%) reported that all 5 were generally available.  
 
Of the 33 countries that did not report any quality indicators, 8 were low-income (44% of 
the region), 11 were lower-middle (42%), 10 were upper-middle (30%), and 4 were high-
income (9%). Of the 26 countries that reported all 5 quality indicators were generally 
available, 0 were low-income, 3 were lower-middle (12% of region), 6 were upper-middle 
(18%), and 17 were high-income (36% of region). There was a statistically significant 
difference in quality reporting among the four income groups (χ2=21.1; p<0.001).  
 
Discussion 
The 2018 GKHA survey identified that most countries offer conservative kidney 
management in some form. However, it was not clear whether it was offered because it was 
medically advised or because KRT was not possible (i.e., choice-restricted). Only 38% of 
countries with conservative kidney management offer easily accessible services. The 
quality of care delivery across countries varied but was poor overall. Respondents from 
high-income countries reported higher quality of conservative kidney management 
compared to those from countries of lower economic standing. KRT was available in all 28 
countries that did not offer conservative kidney management. 
 
Understanding conservative kidney management as a treatment modality 
Compared to other treatment options for kidney failure, conservative kidney management 
is a relatively new treatment modality and there are still several unknowns with respect to 
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how it should be adopted in practice and optimally delivered12. In 2015, the KDIGO 
organization hosted a conference to review evidence and develop recommendations for 
managing advanced CKD, including addressing conservative kidney management2. Only 
last year, the National Institute for Health and Care Excellence (NICE) published a 
document to expand awareness and understanding about the various components of 
conservative kidney management13. Efforts to disseminate these guidelines internationally 
to promote a standard practice in delivering conservative kidney management may help 
reduce the variability of care for people with kidney failure that do not receive KRT.  
 
Optimal conservative kidney management delivery 
The quality of conservative kidney management varies not only across countries, but likely 
will vary within countries and even within centers depending on individual nephrologist 
beliefs, attitudes and ability or willingness to communicate about conservative kidney 
management and prognosis. Efforts to reduce this variability through appropriate 
guidelines, communication, and training are therefore important to ensure not only high 
quality but also equity of conservative kidney management care. Establishing conservative 
kidney management programs that address elements prioritized by patients, families, and 
healthcare providers14 is important to ensure patients receive the best quality of  care 
possible. 
 
Deciding between KRT and conservative kidney management 
The decision to choose between KRT and conservative kidney management is complex for 
both healthcare providers and patients. A significant reason behind the difficulty in making 
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a decision is likely related to the limited evidence regarding whom would benefit more 
from, or prefer, conservative kidney management, compared to dialysis. To date, all 
research exploring non-dialysis care has utilized observational studies, and therefore is 
potentially vulnerable to performance bias, since people who opt for dialysis may have 
different characteristics than those who choose conservative kidney management12. 
Secondly, most studies do not report on the same outcome, and the outcomes chosen for 
reporting may not be those that are most important to patients12. Most studies focus on 
survival as the main outcome measure, which may miss the fact that quality of life and 
symptom control may be more important measures from patients’ point of view. Pragmatic, 
realist, randomized controlled trials, such as the Prepare for Kidney Care trial15 that 
involve a number of clinical and patient-centered outcomes, may help improve the quality 
of the evidence and subsequently guide healthcare providers and patients with decision-
making. 
 
Utilizing processes to support patients, families, and healthcare providers make decisions 
may also help patients receive the most appropriate care. Decision aids16, 17 that inform 
patients about different options for treatment of kidney failure may encourage shared 
decision-making and help identify the most appropriate pathway. While there are a 
number of decision aids targeted at KRT, few focus on the decision between dialysis and 
non-dialysis care18. Currently the few decision aids available with a specific focus on 
choosing dialysis or conservative kidney management include the Conservative Kidney 
Management Patient Decision Aid, the Ottawa tool, OPTIONS18 and one developed by the 
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Renal Team at St. George and Sutherland Hospitals in Australia19., These should offer a 
helpful resource for providers, patients, and families in the future.   
 
Implications for research, policy, and practice 
There are several gaps in conservative kidney management delivery worldwide. To 
increase the adoption of high quality care around the world, a number of actions will likely 
be required (Box 1).  
Box 1. Recommendations for how to improve conservative kidney management 
accessibility and quality worldwide.* 
 
Increase the awareness of conservative kidney management as a viable treatment 
modality among patients and families, healthcare providers, and policymakers, and 
clarify its definition and standard of care. 
 
Identify the barriers to conservative kidney management availability, accessibility, 
and quality, so that strategies can be developed to increase capacity.  
 
Develop policies to ensure that conservative kidney management is optimal and that 
conservative kidney management is not seen as solely palliative care for those that 
can not receive KRT. 
 
Expand the evidence to provide better information regarding the outcomes 
associated with conservative kidney management as well as characteristics of 
patients who are most suitable for this treatment option. 
 
Disseminate guidelines that are accessible globally and adaptable to each local 
context. 
 
Support shared decision-making among healthcare providers, patients and families; 
Understand the current barriers that countries are experiencing with conservative 
kidney management delivery. 
 
Provide government-funded services essential for conservative kidney management, 
such as healthcare provider training, symptom management and psychological 
support. 
 
* Davison SN, Levin A, Moss AH, et al. Executive summary of the KDIGO Controversies Conference on Supportive Care in 
Chronic Kidney Disease: developing a roadmap to improving quality care. Kidney International 2015; 88: 447-459. 
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Additionally, the ISN is developing an kidney failure strategic plan as a follow-up to the 
Harris et al. paper on integrated kidney failure care20. This 5-10 year strategy will use 
working groups to design activities and deliverables related to monitoring, dialysis, 
resources, and support21. More information will be available over the coming year. 
Additionally, the ISN is collaborating with the WHO to develop a technical package for 
setting up maintenance dialysis programs, suitable for low resource settings, which also 
includes discussion of conservative kidney management. 
 
Similar to other questionnaires, our survey has the potential for subjectivity (social 
desirability bias), and was highly dependent on respondents’ knowledge, expertise, and 
perceptions. However, respondents were informed their identity would remain 
confidential in an attempt to reduce the potential for bias. The survey questions were 
assessed for face validity; however, the accuracy of our findings depends on how correctly 
respondents represented the status of services in their country. We therefore worked 
closely with the International Society of Nephrology’s Regional Boards to select 
respondents with a range of kidney care knowledge and expertise while ensuring adequate 
regional representation, and corroborated findings with regional leaders. Regardless, there 
are risks that survey items were unclear. For example, just over 80% of countries in our 
survey reported that conservative kidney management was available.  
 
Even though the survey provided a definition of conservative kidney management, it is 
possible that the availability of services was overestimated if conservative kidney 
management was understood to mean simply managing kidney failure in the absence of 
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dialysis or transplantation. Additionally, the type of conservative kidney management 
offered (i.e., choice-restricted or chosen/medically advised) was presented as independent 
items instead of a mutually exclusive option and therefore, was likely difficult to interpret. 
Lastly, only countries with available stakeholders were invited to complete the survey. It is 
possible that excluding countries that did not respond to the survey might have 
contributed to an over-estimation of capacity if the reason they did not participate was due 
to limited information or resources or political focus on kidney care. However, we received 
representation of 98% of the global population and therefore, the proportion of the global 
population excluded from these 36 countries was likely minimal. 
 
Conclusions 
Overall, most countries offer conservative kidney management, but it was not always clear 
whether it was selected because it was medically advised or because KRT was not possible 
(i.e., choice-restricted). Several gaps were reported across most quality indicators, 
including limited healthcare provider training for conservative kidney management 
delivery; shared decision-making; psychological, cultural, or spiritual support; and the use 
of multidisciplinary teams. These gaps were particularly notable in low-income countries. 
Efforts to increase the awareness, standardization, and uptake of practices recommended 
for conservative kidney management are needed to ensure high quality of care. 
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Is conservative kidney management  
available in your country? 
Accessibility 


























Overall 124 (81) 28 (18) 2 (1) 154 47 54 14 0 9 124 
ISN regions: 
           
Africa 33 (80) 8 (20) 0 (0) 41 5 (15) 16 (48) 8 (24) 0 (0) 4 (12) 33 
E & C Europe 18 (95) 1 (5) 0 (0) 19 8 (44) 10 (56) 0 (0) 0 (0) 0 (0) 18 
Latin America 8 (44) 10 (56) 0 (0) 18 0 (0) 7 (39) 1(13) 0 (0) 0 (0) 8 
Middle East 9 (82) 2 (18) 0 (0) 11 3 (33) 4 (44) 0 (0) 0 (0) 2 (22) 9 
NIS & Russia 4 (57) 3 (43) 0 (0) 7 1 (25) 3 (75) 0 (0) 0 (0) 0 (0) 4 
NAC 6 (67) 3 (33) 0 (0) 9 5 (83) 0 (0) 1 (17) 0 (0) 0 (0) 6 
N & E Asia 7 (100) 0 (0) 0 (0) 7 1 (14) 6 (86) 0 (0) 0 (0) 0 (0) 7 
OSEA 14 (93) 1 (7) 0 (0) 15 7 (50) 3 (21) 4 (29) 0 (0) 0 (0) 14 
South Asia 7 (100) 0 (0) 0 (0) 7 1 (14) 3 (43) 0 (0) 0 (0) 3 (43) 7 
Western Europe 18 (90) 0 (0) 2 (10) 20 16 (89) 2 (11) 0 (0) 0 (0) 0 (0) 18 
World Bank  
Income Group: 
           
Low 18 (82) 4 (18) 0 (0) 22 0 (0) 10 (56) 5 (28) 0 (0) 3 (17) 18 
Lower-middle 26 (74) 9 (26) 0 (0) 35 6 (23) 12 (46) 4 (15) 0 (0) 4 (15) 26 
Upper-middle 33 (80) 8 (20) 0 (0) 41 9 (27) 18 (55) 5 (15) 0 (0) 1 (3)  33 
High 47 (84) 7 (13) 2 (3) 56 32 (68) 14 (30) 0 (0) 0 (0) 1 (2) 47 
 
1Total countries that responded to questions related to conservative kidney management (160 in total responded to the 2016 GKHA questionnaire).  
 
CKM = conservative kidney management; E & C Europe = Eastern and Central Europe; NAC = North America and the Caribbean; NIS = newly independent states; 
N & E Asia = North and East Asia 
 
Row % totals may not sum to 100% due to rounding.   
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Table 2. Availability of kidney replacement therapies, and funding sources, among countries reporting an absence of 
conservative kidney management. 
 










Botswana Upper-middle ✓ ✓ X Mix (govt + private) 
Ethiopia Low ✓ ✓ ✓ Mix (govt + private) 
Mauritania Lower-middle ✓ X X Govt (no fees) 
Sierra Leone Low ✓ X X Other 
Sudan Lower-middle ✓ ✓ ✓ Multiple 
Swaziland Lower-middle ✓ ✓ X Govt (some fees) 
Tanzania Low ✓ X ✓ Mix (govt + private) 




Lithuania High ✓ ✓ ✓ Govt (no fees) 
Latin 
America 
Bolivia Lower-middle ✓ ✓ ✓ Mix (govt + private) 
Brazil Upper-middle ✓ ✓ ✓ Govt (no fees) 
Chile High ✓ ✓ ✓ Govt (some fees) 
El Salvador Lower-middle ✓ ✓ ✓ Mix (govt + private) 
Guatemala Lower-middle ✓ ✓ ✓ Mix (govt + private) 
Mexico Upper-middle ✓ ✓ ✓ Govt (some fees) 
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Peru Upper-middle ✓ ✓ ✓ Mix (govt + private) 
Puerto Rico High ✓ ✓ ✓ Mix (govt + private) 
Uruguay High ✓ ✓ ✓ Mix (govt + private) 




Lower-middle ✓ ✓ ✓ Govt (no fees) 
West Bank 
and Gaza 
Lower-middle ✓ ✓ ✓ Govt (no fees) 
NIS and 
Russia 
Belarus Upper-middle ✓ ✓ ✓ Govt (no fees) 
Kazakhstan Upper-middle ✓ ✓ ✓ Govt (no fees) 
Russian 
Federation 







High ✓ X ✓ Govt (no fees) 
St. Kitts and 
Nevis 
High ✓ ✓ X Private 
Trinidad and 
Tobago 




Cambodia Lower-middle ✓ X X Private 
 
✓ = Available     X  = Not Available  
 
Govt (no fees) = Government (no fees at point of delivery)  
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Govt (some fees) = Government (some fees at point of delivery)  
Mix (govt + private) = Mix of government (public) and private  
Private = Private (solely out-of-pocket)  
Multiple = Multiple sources (programs provided by government, non-government organizations, and communities)   
Other = Other funding sources 
 
E & C Europe = Eastern and Central Europe; ISN = international society of nephrology; KRT = kidney replacement therapy 
(dialysis and transplantation, excludes conservative kidney management); NAC = North America and the Caribbean; NIS = 
newly independent states; N & E Asia = North and East Asia 
 
8 countries, that do not have conservative kidney management available, also do not offer peritoneal dialysis: Ethiopia 
(Africa), Mauritania (Africa), Sierra Leone (Africa), Tanzania (Africa), Syrian Arab Republic (Middle East), West Bank and Gaza 
(Middle East), Antigua and Barbuda (North America and the Caribbean), and Cambodia (Oceania and South East Asia).  
 
7 countries, that do not have conservative kidney management available, also do not offer kidney transplantation: Botswana 
(Africa), Mauritania (Africa), Sierra Leone (Africa), Swaziland (Africa), Zimbabwe (Africa), St. Kitts and Nevis (North America 




Table 3. Number of countries with conservative kidney management available and components of care that are 























Overall 124 57 (46) 40 (32) 80 (65) 45 (36) 31 (25) 
ISN regions:       
Africa 33 11 (33) 9 (27) 17 (52) 7 (21) 4 (12) 
E & C Europe 18 9 (50) 6 (33) 14 (78) 6 (33) 6 (33) 
Latin America 8 3 (34) 0 (0) 4 (50) 1 (13) 0 (0) 
Middle East 9 2 (22) 1 (11) 7 (78) 1 (11) 1 (11) 
NIS & Russia 4 2 (50) 1 (25) 2 (50) 2 (50) 1 (25) 
NAC 6 5 (83) 4 (67) 6 (100) 3 (50)  2 (33) 
N & E Asia 7 5 (71) 1 (14) 5 (71) 2 (29) 1 (14) 
OSEA 14 7 (50) 5 (36) 6 (43) 7 (50) 6 (43) 
South Asia 7 0 (0) 0 (0) 2 (29) 4 (57) 1 (14) 
Western Europe 18 13 (72) 13 (72) 17 (94) 12 (67) 9 (50) 
World Bank 
Income Group: 
      
Low 18 4 (22) 2 (11) 9 (50) 3 (17) 0 (0) 
Lower-middle 26 6 (23) 7 (27) 12 (46) 8 (31) 6 (23) 
Upper-middle 33 16 (48) 8 (24) 18 (55) 10 (30) 7 (21) 
High 47 31 (66) 23 (49) 41 (87) 24 (51) 18 (38) 
 
*Davison SN, Levin A, Moss AH, et al. Executive summary of the KDIGO Controversies Conference on Supportive Care in 




Generally available means in 50% or more centres (hospitals or clinics). Other response options (not shown) included: 
Generally not available (in less than 50% of centres), never, or unknown.  
 
CKM = conservative kidney management; E & C Europe = Eastern and Central Europe; NAC = North America and the 
Caribbean; NIS = newly independent states; N & E Asia = North and East Asia 
 
Row totals may not sum to 100% due to rounding.  
